Avenzo Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation small-molecule and antibody-drug conjugate (ADC) therapies for oncology. Founded in 2022 by veterans of Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B in 2022), the San Diego-based company targets cancers with high unmet medical needs. The company has raised over $60M in Series B financing with backing from OrbiMed, Foresite Capital, SR One, NEA, Lilly Asia Ventures, Sands Capital, and others.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account